Pelacarsen Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Pelacarsen Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Phase 3
Highest phase
19
Registered trials
4
Result records
2
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Pelacarsen can convert its ASO profile and Lp(a) biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Pelacarsen (query alias: pelacarsen) |
|---|---|
| Modality / target | ASO; Lp(a); lipoprotein(a) inhibitors |
| Highest global status | Phase 3 |
| Originator | Ionis Pharmaceuticals, Inc. |
| Active developers | Novartis Pharma AG, Novartis Pharma Stein AG, Novartis Pharmaceuticals Canada, Inc. |
The MCP disease footprint includes Acute Coronary Syndrome, Non-St Elevated Myocardial Infarction, ST Elevation Myocardial Infarction. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07517263 | Phase 3 | Recruiting | 5700 | Number of participants with Adverse events |
| NCT06875973 | Phase 3 | Recruiting | 599 | Incidence of Adverse events (AEs) or serious adverse events (SAEs) |
| NCT07625306 | Phase 3 | Not yet recruiting | 240 | Change in log-transformed Lp(a) concentration |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial
Phase 3; n=51; evaluation: Positive. Reported fields: LA sessions = 0.93 Unit ; LA sessions = 0.16 Unit
Early health technology assessment of gene silencing therapies for lowering lipoprotein(a) in the secondary prevention of coronary heart disease
Phase 3; n=not disclosed; evaluation: Positive. Reported fields: -; Discounted QALYs saved = 0.87 QALYs
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) Administered Subcutaneously to Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD)
Phase 2; n=286; evaluation: not stated. Reported fields: Percent Change From Baseline in Fasting Lipoprotein A [Lp(a)] at the Primary Analysis Time Point(Geometric Mean) = -6 percent change (95% Confidence Interval, -21 to 12); Percent Change From Baseline in Fasting Lipoprotein A [Lp(a)] at the Primary Analysis Time Point(Geometric Mean): Mean Difference in % CFB = -31(95% CI, -46 to -12), P-Value = 0.0032; Mean Difference in % CFB = -54(95% CI, -64 to -41), P-Value = <.0001; Mean Difference in % CFB = -70(95% CI, -77 to -62), P-Value = <.0001; Mean Difference in % CFB = -56(95% CI, -65 to -43), P-Value = <.0001; Mean Difference in % CFB = -78(95% CI, -83 to -72), P-Value = <.0001; Percent Change From Baseline in Fasting Lipoprotein A [Lp(a)] at the Primary Analysis Time Point(Geometric Mean): Mean Difference in % CFB = -31(95% CI, -46 to -12), P-Value = 0.0032; Mean Difference in % CFB = -54(95% CI, -64 to -41), P-Value = <.0001; Mean Difference in % CFB = -70(95% CI, -77 to -62), P-Value = <.0001; Mean Difference in % CFB = -56(95% CI, -65 to -43), P-Value = <.0001; Mean Difference in % CFB = -78(95% CI, -83 to -72), P-Value = <.0001
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Pelacarsen addresses Acute Coronary Syndrome, Non-St Elevated Myocardial Infarction, ST Elevation Myocardial Infarction. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—ASO—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2023-01-09 | Royalty Pharma agrees to buy Ionis Pharma royalties for $1.125 bln | Approved | US$1,125.0M stated total |
| 2017-01-06 | Ionis and Akcea Enter into Strategic Collaboration with Global Pharmaceutical Company to Develop and Commercialize AKCEA-APO(a)-L Rx and AKCEA-APOCIII-L Rx | Phase 1/2 | US$75.0M upfront |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Compounds and methods for inhibiting lpa”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
